ChemoCentryx downgraded by Raymond James with a new price target
$CCXI
Raymond James downgraded ChemoCentryx from Strong Buy to Outperform and set a new price target of $51.00 from $120.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/4/2022 | $81.00 | Buy | Canaccord Genuity |
| 11/10/2021 | $107.00 → $110.00 | Strong Buy | Raymond James |
| 10/11/2021 | $14.00 → $38.00 | Underweight → Neutral | JP Morgan |
| 10/11/2021 | $64.00 | Mkt Perform → Outperform | SVB Leerink |
| 10/11/2021 | $62.00 → $107.00 | Outperform → Strong Buy | Raymond James |
| 10/8/2021 | $62.00 → $107.00 | Outperform → Strong Buy | Raymond James |
| 10/8/2021 | Neutral → Overweight | Piper Sandler | |
| 7/7/2021 | $26.00 → $31.00 | Hold → Buy | Stifel |
4 - Churchill Capital Corp XI (0002074973) (Issuer)
Submission status for CHEMOCENTRYX, INC.'s drug TAVNEOS (ORIG-1) with active ingredient AVACOPAN has changed to 'Approval' on 10/07/2021. Application Category: NDA, Application Number: 214487, Application Classification: Type 1 - New Molecular Entity
Experienced public company finance executive joins Agility as company expands commercial momentum and prepares to become the first publicly listed U.S. pure-play humanoid robotics company.SALEM, Ore., July 23, 2026 /PRNewswire/ -- Agility Robotics, a leading humanoid robotics and Physical AI company, today announced the appointment of Michael Beer as Chief Financial Officer as the company continues to strengthen its executive leadership team ahead of its planned public listing through its previously announced business combination with Churchill Capital Corp XI (NASDAQ:CCXI). As part of this planned evolution of the leadership t
Bay Area facility will advance the AI technologies that enable its humanoid robot, Digit, to learn new skills, supporting expanded capabilities across commercial deployments.FREMONT, Calif., July 16, 2026 /PRNewswire/ -- Agility, a leading humanoid robotics and Physical AI company, today announced the opening of its new Fremont, California, facility designed to accelerate Physical AI developments that directly improve performance in customer operations. The new site will serve as the company's software and capabilities hub, where engineering teams will train, test and advance the AI technologies that enable Agility's humanoid, Digit, to learn new skills and perform more sophisticated tasks i
Transaction Expected to Create The Only Publicly Listed Pure-Play Humanoid Company with Proven, Active Commercial Deployments Agility Robotics, Inc. ("Agility" or the "Company") creator of the general-purpose humanoid robot Digit, and Churchill Capital Corp XI (NASDAQ:CCXI) ("CCXI" or "Churchill XI"), a special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"). The submission of the Registration Statement marks an important milestone toward the completion of the previously disclosed proposed business combination between Agility and
3 - Churchill Capital Corp XI (0002074973) (Issuer)
3 - Churchill Capital Corp XI (0002074973) (Issuer)
4 - Churchill Capital Corp XI (0002074973) (Issuer)
Canaccord Genuity resumed coverage of ChemoCentryx with a rating of Buy and set a new price target of $81.00
Raymond James reiterated coverage of ChemoCentryx with a rating of Strong Buy and set a new price target of $110.00 from $107.00 previously
JP Morgan upgraded ChemoCentryx from Underweight to Neutral and set a new price target of $38.00 from $14.00 previously
425 - Churchill Capital Corp XI (0002074973) (Subject)
425 - Churchill Capital Corp XI (0002074973) (Subject)
8-K - Churchill Capital Corp XI (0002074973) (Filer)
SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. "With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Jennifer's values closely align with our organization, and we are confident this addition
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug de
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. “Susan Kanaya’s many fundamental contributions have been key to ChemoCentryx’s growth and prosperity,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Over many formative years of our enterprise, she ensured our strong financial position, allowing us to achieve our operational plans and thus increasing shareholder value while serving patients’ needs. As a
TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022. About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer.
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (International). The conference ID number is 9726781. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast wil
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)